Latest Period
Q1 2026
Security Snapshot
Black Diamond Therapeutics, Inc. - Common Stock, par value $0.0001 per share (BDTX) Institutional Ownership
CUSIP: 09203E105
13F Institutional Holders and Ownership History from Q1 2020 to Q1 2026
Institutions Reporting
102
Shares (Excl. Options)
38,514,397
Price
$2.13
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- BDTX on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 38,514,397
- Total 13F value
- $82,030,473
- Portfolio coverage rank
- 0%
- Share change
- +643,665
- Value change
- +$540,526
- Number of holders
- 102
- Shares outstanding
- 58,000,000
- SEC-reported price per share
- $2.28
- Insider filing price
- $2.28
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- BDTX - Black Diamond Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 09203E105.
- 102 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 103 to 102 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $92,001,922 to $82,030,473.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 102 institutions filings for Q1 2026.
Security key
09203E105
Latest holder period
Q1 2026
13F holders
102
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
BDTX full holder history
Black Diamond Therapeutics, Inc. SEC filings
Black Diamond Therapeutics, Inc. company facts
Black Diamond Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 09203E105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
BDTX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BB BIOTECH AG | 4.8% | -69% | $4,373,675 | -$9,254,867 | 2,733,547 | -68% | BB Biotech AG | 19 Mar 2025 |
| BlackRock, Inc. | 4.5% | $4,037,634 | 2,523,521 | BlackRock, Inc. | 31 Mar 2025 | |||
| Vestal Point Capital, LP | 1.5% | $2,166,300 | 870,000 | Vestal Point Capital, LP | 31 Dec 2025 |
As of 31 Mar 2026, 102 institutional investors reported holding 38,514,397 shares of Black Diamond Therapeutics, Inc. - Common Stock, par value $0.0001 per share (BDTX). This represents 66% of the company’s total 58,000,000 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
59%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 18% | 10,563,103 | -0.41% | 0.02% | $22,500,000 |
| NEA Management Company, LLC | 7.7% | 4,448,757 | 0% | 0.54% | $9,475,852 |
| ACADIAN ASSET MANAGEMENT LLC | 4% | 2,348,651 | +44% | 0.01% | $4,997,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.2% | 1,850,468 | 0% | 0% | $3,941,497 |
| RENAISSANCE TECHNOLOGIES LLC | 2.8% | 1,643,747 | +73% | 0.01% | $3,501,181 |
| DIMENSIONAL FUND ADVISORS LP | 2.2% | 1,301,664 | +52% | 0% | $2,772,069 |
| BlackRock, Inc. | 1.9% | 1,106,840 | +25% | 0% | $2,357,570 |
| Connor, Clark & Lunn Investment Management Ltd. | 1.8% | 1,058,397 | +62% | 0.01% | $2,254,386 |
| MACKENZIE FINANCIAL CORP | 1.5% | 844,835 | +140% | 0% | $1,799,499 |
| MARSHALL WACE, LLP | 1.4% | 836,266 | -25% | 0% | $1,781,245 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.4% | 834,570 | -20% | 0% | $1,777,634 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 1.2% | 723,477 | +317% | 0.03% | $1,541,006 |
| GOLDMAN SACHS GROUP INC | 1.2% | 684,418 | +110% | 0% | $1,457,811 |
| FMR LLC | 1.1% | 623,827 | +15% | 0% | $1,328,751 |
| UBS Group AG | 0.97% | 564,838 | +119% | 0% | $1,203,105 |
| Man Group plc | 0.96% | 559,700 | +330% | 0% | $1,192,161 |
| WINTON GROUP Ltd | 0.93% | 538,259 | +28% | 0.04% | $1,146,492 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.93% | 536,575 | +6.1% | 0% | $1,143,769 |
| AWM Investment Company, Inc. | 0.91% | 525,000 | -16% | 0.12% | $1,118,250 |
| Balyasny Asset Management L.P. | 0.88% | 510,811 | 0% | $1,088,027 | |
| CITADEL ADVISORS LLC | 0.87% | 502,652 | +18% | 0% | $1,070,649 |
| NORTHERN TRUST CORP | 0.8% | 464,708 | -1.7% | 0% | $989,828 |
| D. E. Shaw & Co., Inc. | 0.63% | 363,921 | -45% | 0% | $775,152 |
| GLOBEFLEX CAPITAL L P | 0.53% | 305,276 | 0% | 0.1% | $650,238 |
| STIFEL FINANCIAL CORP | 0.48% | 278,645 | +1.3% | 0% | $593,515 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
25
Latest
Q1 2026
Rows shown
1-25 of 25
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 38,514,397 | $82,030,473 | +$540,526 | $2.13 | 102 |
| 2025 Q4 | 37,853,431 | $92,001,922 | -$6,001,452 | $2.43 | 103 |
| 2025 Q3 | 38,780,810 | $146,973,938 | +$5,639,493 | $3.79 | 89 |
| 2025 Q2 | 38,616,493 | $95,766,554 | -$4,378,949 | $2.48 | 92 |
| 2025 Q1 | 40,656,241 | $63,017,852 | -$11,756,469 | $1.55 | 83 |
| 2024 Q4 | 47,903,925 | $102,516,125 | -$13,785,684 | $2.14 | 85 |
| 2024 Q3 | 48,717,118 | $211,892,256 | +$1,570,817 | $4.35 | 95 |
| 2024 Q2 | 46,760,739 | $217,913,327 | +$31,657,196 | $4.66 | 88 |
| 2024 Q1 | 39,430,252 | $199,910,697 | +$10,671,909 | $5.07 | 86 |
| 2023 Q4 | 38,119,952 | $107,120,051 | +$4,413,540 | $2.81 | 73 |
| 2023 Q3 | 37,180,210 | $106,709,201 | -$21,943,325 | $2.87 | 71 |
| 2023 Q2 | 41,421,828 | $209,176,335 | +$105,453,106 | $5.05 | 72 |
| 2023 Q1 | 21,491,972 | $40,617,428 | +$846,555 | $1.89 | 47 |
| 2022 Q4 | 21,053,167 | $37,894,305 | -$721,593 | $1.80 | 56 |
| 2022 Q3 | 21,487,475 | $36,340,473 | -$284,945 | $1.69 | 57 |
| 2022 Q2 | 21,498,645 | $52,895,689 | -$3,549,739 | $2.46 | 56 |
| 2022 Q1 | 22,887,182 | $64,088,307 | -$2,429,770 | $2.77 | 69 |
| 2021 Q4 | 23,198,177 | $123,630,624 | -$12,989,218 | $5.33 | 83 |
| 2021 Q3 | 24,374,413 | $206,301,397 | -$11,175,534 | $8.46 | 89 |
| 2021 Q2 | 25,397,669 | $309,589,838 | -$81,437,251 | $12.19 | 97 |
| 2021 Q1 | 29,083,953 | $705,520,847 | -$7,557,586 | $24.26 | 109 |
| 2020 Q4 | 28,616,097 | $917,170,806 | +$140,401,559 | $32.05 | 109 |
| 2020 Q3 | 23,764,080 | $718,480,421 | +$753,590 | $30.23 | 88 |
| 2020 Q2 | 22,835,597 | $959,367,654 | +$39,864,306 | $42.16 | 79 |
| 2020 Q1 | 22,285,008 | $555,219,061 | +$555,219,061 | $24.95 | 65 |